Login to Your Account



Solid Biosciences lands $50M series C to advance DMD gene therapy

By Michael Fitzhugh
Staff Writer

Thursday, March 30, 2017

Solid Biosciences LLC completed the initial close of a $50 million series C financing that it said will help move its experimental gene therapy for DMD into the clinic in the second half of this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription